Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 13/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL815781 | 0.96 | RAPGEF4 (0.46) | RAPGEF4LMNAALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL813865 | 0.96 | RAPGEF4 (0.46) | RAPGEF4LMNAALDH1A1GAAMAPT | |
| SCHEMBL812880 | 0.96 | RAPGEF4 (0.50) | RAPGEF4LMNAALDH1A1GAAMAPT | |
| SCHEMBL814154 | 0.93 | RAPGEF4 (0.48) | RAPGEF4LMNAALDH1A1GAAMAPT | |
| SCHEMBL814425 | 0.93 | RAPGEF4 (0.48) | RAPGEF4LMNAALDH1A1GAAMAPT | |
| SCHEMBL813197 | 0.93 | RAPGEF4 (0.48) | RAPGEF4LMNAALDH1A1GAAMAPT | |
| SCHEMBL816160 | 0.93 | RAPGEF4 (0.48) | RAPGEF4LMNAALDH1A1GAAMAPT | |
| SCHEMBL814620 | 0.93 | RAPGEF4 (0.48) | RAPGEF4LMNAALDH1A1GAAMAPT | |
| Bromide SCHEMBL813373 | 0.92 | RAPGEF4 (0.40) | RAPGEF4LMNAALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL814581 | 0.91 | RAPGEF4 (0.46) | RAPGEF4LMNAALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371803-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-05-13 | — | — | US | claimed |
| US-20070066776-A1 | Catalyst composition II | SOLAN GREGORY A | 2007-03-22 | — | — | US | claimed |
| US-7189791-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-03-13 | — | — | US | claimed |
| US-20040266961-A1 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-12-30 | — | — | US | claimed |
| US-8058372-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20080319147-A1 | Catalyst Composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2008-12-25 | — | — | US | disclosed |
| US-7371803-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070066776-A1 | Catalyst composition II | SOLAN GREGORY A | 2007-03-22 | — | — | US | disclosed |
| US-7189791-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20040266961-A1 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266961-A1 | Catalyst composition II | MLX, CBX2, BMX | RAPGEF4 4437/4885LMNA 25/4885ALDH1A1 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.